View Item 

Show simple item record

Tocilizumab Prevents Progression of Early Systemic Sclerosis–Associated Interstitial Lung Disease
dc.contributor.authorRoofeh, David
dc.contributor.authorLin, Celia J. F.
dc.contributor.authorGoldin, Jonathan
dc.contributor.authorKim, Grace Hyun
dc.contributor.authorFurst, Daniel E.
dc.contributor.authorDenton, Christopher P.
dc.contributor.authorHuang, Suiyuan
dc.contributor.authorKhanna, Dinesh
dc.date.accessioned2021-07-01T20:12:23Z
dc.date.available2022-08-01 16:12:23en
dc.date.available2021-07-01T20:12:23Z
dc.date.issued2021-07
dc.identifier.citationRoofeh, David; Lin, Celia J. F.; Goldin, Jonathan; Kim, Grace Hyun; Furst, Daniel E.; Denton, Christopher P.; Huang, Suiyuan; Khanna, Dinesh (2021). "Tocilizumab Prevents Progression of Early Systemic Sclerosis–Associated Interstitial Lung Disease." Arthritis & Rheumatology (7): 1301-1310.
dc.identifier.issn2326-5191
dc.identifier.issn2326-5205
dc.identifier.urihttps://hdl.handle.net/2027.42/168321
dc.publisherMarcel Dekker
dc.publisherWiley Periodicals, Inc.
dc.titleTocilizumab Prevents Progression of Early Systemic Sclerosis–Associated Interstitial Lung Disease
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelRheumatology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/168321/1/art41668.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/168321/2/art41668_am.pdf
dc.identifier.doi10.1002/art.41668
dc.identifier.sourceArthritis & Rheumatology
dc.identifier.citedreferenceSteen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994; 37: 1283 – 9.
dc.identifier.citedreferenceGoh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177: 1248 – 54.
dc.identifier.citedreferenceTashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655 – 66.
dc.identifier.citedreferenceTashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma‐related interstitial lung disease (SLS II): a randomised controlled, double‐blind, parallel group trial. Lancet Respir Med 2016; 4: 708 – 19.
dc.identifier.citedreferenceHoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, et al. A multicenter, prospective, randomized, double‐blind, placebo‐controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006; 54: 3962 – 70.
dc.identifier.citedreferenceDistler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for systemic sclerosis‐associated interstitial lung disease. N Engl J Med 2019; 380: 2518 – 28.
dc.identifier.citedreferenceMahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85: 751 – 8.
dc.identifier.citedreferenceRoofeh D, Khanna D. Management of systemic sclerosis: the first five years [review]. Curr Opin Rheumatol 2020; 32: 228 – 37.
dc.identifier.citedreferenceRoofeh D, Jaafar S, Vummidi D, Khanna D. Management of systemic sclerosis‐associated interstitial lung disease [review]. Curr Opin Rheumatol 2019; 31: 241 – 9.
dc.identifier.citedreferenceKhanna D, Tashkin DP, Denton CP, Renzoni EA, Desai SR, Varga J. Aetiology, risk factors, and biomarkers in systemic sclerosis with interstitial lung disease. Am J Respir Crit Care Med 2020; 201: 650 – 60.
dc.identifier.citedreferenceKhanna D, Nagaraja V, Tseng CH, Abtin F, Suh R, Kim G, et al. Predictors of lung function decline in scleroderma‐related interstitial lung disease based on high‐resolution computed tomography: implications for cohort enrichment in systemic sclerosis‐associated interstitial lung disease trials. Arthritis Res Ther 2015; 17: 1 – 10.
dc.identifier.citedreferenceAllanore Y, Simms R, Distler O, Trojanowska M, Pope J, Denton CP, et al. Systemic sclerosis [review]. Nat Rev Dis Prim 2015; 1: 1 – 21.
dc.identifier.citedreferenceSteen V. Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis 2003; 62: 97 – 9.
dc.identifier.citedreferenceWinstone TA, Assayag D, Wilcox PG, Dunne JV, Hague CJ, Leipsic J, et al. Predictors of mortality and progression in scleroderma‐associated interstitial lung disease: a systematic review. Chest 2014; 146: 422 – 36.
dc.identifier.citedreferenceSilver RM. Systemic sclerosis: choosing patients wisely when treating interstitial lung disease [review]. Nat Rev Rheumatol 2017; 13: 455 – 6.
dc.identifier.citedreferenceBernstein EJ, Khanna D, Lederer DJ. Screening high‐resolution computed tomography of the chest to detect interstitial lung disease in systemic sclerosis: a global survey of rheumatologists. Arthritis Rheumatol 2018; 70: 971 – 2.
dc.identifier.citedreferenceHoffmann‐Vold AM, Maher TM, Philpot EE, Ashrafzadeh A, Barake R, Barsotti S, et al. The identification and management of interstitial lung disease in systemic sclerosis: evidence‐based European consensus statements. Lancet Rheumatol 2020; 2: E71 – 83.
dc.identifier.citedreferenceSuliman YA, Dobrota R, Huscher D, Nguyen‐Kim TD, Maurer B, Jordan S, et al. Pulmonary function tests: high rate of false‐negative results in the early detection and screening of scleroderma‐related interstitial lung disease. Arthritis Rheumatol 2015; 67: 3256 – 61.
dc.identifier.citedreferenceHatabu H, Hunninghake GM, Richeldi L, Brown KK, Wells AU, Remy‐Jardin M, et al. Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. Lancet Respir Med 2020; 8: 726 – 37.
dc.identifier.citedreferenceMontesi SB, Caravan P. Novel imaging approaches in systemic sclerosis‐associated interstitial lung disease [review]. Curr Rheumatol Rep 2019; 21: 25.
dc.identifier.citedreferenceO’Donnell D. Physiology of interstitial lung disease. In: Schwartz M, King T, editors. Interstitial lung disease. Hamilton: Marcel Dekker; 1998. p. 51 – 70.
dc.identifier.citedreferenceGrippi MA, Tino G. Pulmonary function testing. In: Grippi MA, Elias JA, Fishman JA, Kotloff RM, Pack AI, Senior RM, Siegel MD, editors. Fishman’s pulmonary diseases and disorders, 5th ed. New York; McGraw‐Hill: 2015. p. 1 – 75.
dc.identifier.citedreferenceDenton CP, Ong VH, Xu S, Chen‐Harris H, Modrusan Z, Lafyatis R, et al. Therapeutic interleukin‐6 blockade reverses transforming growth factor‐β pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis. Ann Rheum Dis 2018; 77: 1362 – 71.
dc.identifier.citedreferenceDenton CP, Khanna D. Systemic sclerosis [review]. Lancet 2017; 390: 1685 – 99.
dc.identifier.citedreferenceDe Lauretis A, Veeraraghavan S, Renzoni E. Connective tissue disease‐associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ? Chron Respir Dis 2011; 8: 53 – 82.
dc.identifier.citedreferenceRoofeh D, Distler O, Allanore Y, Denton CP, Khanna D. Treatment of systemic sclerosis–associated interstitial lung disease: lessons from clinical trials. J Scleroderma Relat Disord 2020; 5: 61 – 71.
dc.identifier.citedreferenceNihtyanova SI, Schreiber BE, Ong VH, Rosenberg D, Moinzadeh P, Coghlan JG, et al. Prediction of pulmonary complications and long‐term survival in systemic sclerosis. Arthritis Rheumatol 2014; 66: 1625 – 35.
dc.identifier.citedreferenceLiu X, Mayes MD, Pedroza C, Draeger HT, Gonzalez EB, Harper BE, et al. Does C‐reactive protein predict the long‐term progression of interstitial lung disease and survival in patients with early systemic sclerosis? Arthritis Care Res (Hoboken) 2013; 65: 1375 – 80.
dc.identifier.citedreferenceAssassi S, Leyva AL, Mayes MD, Sharif R, Nair DK, Fischbach M, et al. Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther 2010; 12: R166.
dc.identifier.citedreferenceDistler O, Volkmann ER, Hoffmann‐Vold AM, Maher TM. Current and future perspectives on management of systemic sclerosis‐associated interstitial lung disease [review]. Expert Rev Clin Immunol 2019; 15: 1009 – 17.
dc.identifier.citedreferenceKhanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 2016; 387: 2630 – 40.
dc.identifier.citedreferenceKhanna D, Lin CJ, Furst DE, Goldin J, Kim G, Kuwana M, et al. Tocilizumab in systemic sclerosis: a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Respir Med 2020; 8: 963 – 74.
dc.identifier.citedreferenceVan den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65: 2737 – 47.
dc.identifier.citedreferenceClements PJ, Lachenbruch PA, Ng SC, Simmons M, Sterz M, Furst DE. Skin score: a semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis. Arthritis Rheum 1990; 33: 1256 – 63.
dc.identifier.citedreferenceGraham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, et al. Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement. Am J Respir Crit Care Med 2019; 200: e70 – 88.
dc.identifier.citedreferenceKim GH, Tashkin DP, Lo P, Brown MS, Volkmann ER, Gjertson DW, et al. Using transitional changes on high‐resolution computed tomography to monitor the impact of cyclophosphamide or mycophenolate mofetil on systemic sclerosis–related interstitial lung disease. Arthritis Rheumatol 2020; 72: 316 – 25.
dc.identifier.citedreferenceGoldin JG, Kim GH, Tseng CH, Volkmann E, Furst D, Clements P, et al. Longitudinal changes in quantitative interstitial lung disease on computed tomography after immunosuppression in the Scleroderma Lung Study II. Ann Am Thorac Soc 2018; 15: 1286 – 95.
dc.identifier.citedreferenceVolkmann ER, Tashkin DP, Sim M, Li N, Khanna D, Roth MD, et al. Cyclophosphamide for systemic sclerosis‐related interstitial lung disease: a comparison of Scleroderma Lung Study I and II. J Rheumatol 2019; 46: 1316 – 25.
dc.identifier.citedreferenceKim HJ, Tashkin DP, Clements P, Li G, Brown MS, Elashoff R, et al. A computer‐aided diagnosis system for quantitative scoring of extent of lung fibrosis in scleroderma patients. Clin Exp Rheumatol 2010; 28 Suppl 62: S26 – 35.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
art41668.pdf
Size:
533.7KB
Format:
PDF
View/Open
Name:
art41668_am.pdf
Size:
852.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.